Tag: AMG 334

January 22, 2018

Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients

Novartis (VTX:NOVN) announced positive results from the Phase IIIb LIBERTY study assessing the efficacy and safety of erenumab (AMG 334)...

migraine market, amgen, novartis

November 17, 2016

Amgen and Novartis Lead the Migraine Market

Novartis and Amgen lead the migraine market after a second late-stage trial yielded positive results.